Thursday, March 7th, 2013 at 11:28 PM
Women with obstructive sleep apnea (OSA) and cardiac symptoms have a 31 percent incidence of cardiac dysfunction. Researchers have recommended use of echocardiograms should be considered in the clinical management of these women.
Obstructive sleep apnea (OSA) is characterized by abnormal pauses in breathing or instances of abnormally low breathing, during sleep. These pauses can last from at least ten seconds to minutes, and may occur five to 30 times or more an hour; this can lead to cardiovascular disease.
Researchers conducted an observational study with an objective to measure the incidence of OSA among pregnant and reproductive women. Read the rest of this entry
Monday, November 19th, 2012 at 10:02 PM
Obstructive Sleep Apnea (OSA) has been associated with increased cancer mortality, but whether it is also associated with cancer incidence is unknown.
Researchers accomplished a detailed investigation whether OSA is associated with increased cancer incidence in a large clinical cohort.
Multicenter, clinical cohort study including consecutive patients investigated for suspected OSA between 2003-2007 in 7 Spanish teaching hospitals. Apnea-hypopnea index (AHI) and percent night-time with oxygen saturation <90% (TSat90) were used as surrogates of OSA severity, both as continuous variables and categorized by tertiles. Cox proportional hazards regression analyses were used to calculate hazard ratios (HR) and 95%CI for cancer incidence after adjusting for confounding variables. Read the rest of this entry
Thursday, November 3rd, 2011 at 9:31 PM
A study appearing in the November 2011 issue of the Journal of Clinical Sleep Medicine finds that obstructive sleep apnea (OSA) patients treated with Provent Sleep Apnea Therapywere not only compliant with the therapy but also showed a reduction in apnea-hypopnea index (AHI).
“This study provides further validation that Provent Therapy is an effective treatment for some OSA patients as it reduces daytime sleepiness, apnea-hypopnea index (AHI), and snoring associated with this prevalent condition,” said Meir Kryger, MD, of Gaylord Sleep Medicine and past president of the American Academy of Sleep Medicine.
“Patients reported wearing the device almost 90% of the nights, which represents very high compliance. The current gold standard, continuous positive airway pressure (CPAP) is very effective but many patients do not use it adequately. Provent represents an important new treatment option for many obstructive sleep apnea patients.” Read the rest of this entry
Sunday, September 25th, 2011 at 11:26 PM
Obstructive sleep apnea (OSA) is a common yet underdiagnosed condition. The aim of our study is to test whether prediabetes and type 2 diabetes are associated with obstructive sleep apnea (OSA) in extremely obese (BMI [greater than or equal to] 40 kg/m2) subjects.
One hundred and thirty seven consecutive extremely obese patients (99 females) from a controlled clinical trial [MOBIL-study (Morbid Obesity treatment, Bariatric surgery versus Intensive Lifestyle intervention Study) (ClinicalTrials.gov number NCT00273104)] underwent somnography with Embletta(R) and a 2-hour oral glucose tolerance test (OGTT). Read the rest of this entry
Thursday, June 23rd, 2011 at 1:09 PM
Transcend, the new wearable sleep apnea therapy device designed by Somnetics International Inc. to be the ultimate travel CPAP, now measures apnea-hypopnea index (AHI). While AHI measurement is not new to CPAPs, it is a new standard feature on Transcend thereby giving users added value at no additional cost.
Used to assess the severity of a patient’s sleep apnea, AHI is a numerical measure that accounts for the number of pauses in breathing per hour of sleep. Leak detection helps assess the appropriateness of the mask used by the patient. In measuring AHI and leak detection, Transcend also helps assess the efficacy of the patient’s pressure setting. Valuable to both patients and doctors, this information can be used to identify issues with the therapy and to determine how changes to the system setup affects overall treatment. Read the rest of this entry
Wednesday, June 15th, 2011 at 8:26 PM
New research that will be presented Saturday, June 11, at the 20th Anniversary Meeting of the American Academy of Dental Sleep Medicine (AADSM) in Minneapolis, Minn., quantified the efficacy of mandibular advancement splints (MAS) using a self-administered, at-home device to monitor snoring and sleep-disordered breathing. Clinical assessment of MAS efficacy in the treatment of snoring and obstructive sleep apnea (OSA) is based predominantly on subjective reports by the patient and partner, and less commonly, on the apnea hypopnea index (AHI), which is the average number of pauses in breathing that occur per hour of sleep. The current study used the Sonomat, a portable, unobtrusive device that has sensors contained within a mattress overlay. These sensors measure AHI by detecting and recording snoring, breathing and body movements.
Results show that MAS treatment reduced the average AHI from 10.3 events per hour to 3.8 events per hour. The respiratory event movement index (RMI), which records more types of events than AHI, was reduced from 15.9 events per hour to 7.6 events per hour. Read the rest of this entry
Monday, May 9th, 2011 at 10:12 PM
ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA).Clinical trial results from the study will be announced at the American Thoracic Society’s International Conference on May 16, 2011 in Denver, CO.
Principal investigator Dr. Daniel Rodenstein, who helmed the clinical trials, will deliver the results, including significant improvements to patient’s Apnea Hypopnea Index (AHI), Oxygen Desaturation Index (ODI), as well as improvements in sleep quality.
“ImThera’s Therapy is safe and shows substantial OSA reduction and sleep improvement in a majority of patients,” said Dr. Rodenstein. “I am looking forward to the American Thoracic Society’s International Conference and the opportunity to share the substantial patient improvements that resulted from the clinical trial.” Read the rest of this entry
Monday, May 2nd, 2011 at 6:48 PM
Inspire™ Upper Airway Stimulation (UAS) therapy is designed to significantly reduce the burden of obstructive sleep apnea by delivering mild stimulation to the upper airway during sleep.
Inspire therapy is a small, fully implantable system that utilizes well-established technologies from the fields of cardiac pacing and neurostimulation. Inspire therapy is currently available only through clinical trials at select medical centers in the United States and Europe.
The airway is dynamic structure…obstructive sleep apnea (OSA) is a dynamic condition…Inspire therapy is a dynamic therapy that works with the body’s physiology to prevent airway obstruction. Read the rest of this entry
Thursday, April 21st, 2011 at 8:00 PM
Ventus Medical Inc reported positive results from a 19-center clinical trial using its FDA-cleared Provent Sleep Apnea Therapy device to treat obstructive sleep apnea. Provent Therapy uses the patient’s own breathing to create expiratory positive airway pressure (EPAP) to keep the airway open during sleep.
“This randomized, sham-controlled study demonstrates that Provent Therapy significantly improves the apnea hypopnea index (AHI), a scale to measure the number of breathing interruptions or stoppages per hour of sleep, as well as subjective sleepiness, as measured by the Epworth Sleepiness Scale (ESS), in patients with obstructive sleep apnea,” said study author Richard B. Berry, MD, professor of medicine at the University of Florida College of Medicine, medical director of the University of Florida and Shands Sleep Disorders Center, and former president of the American Sleep Medicine Foundation. “Importantly, self-reported patient adherence on Provent Therapy was almost 90%.” Read the rest of this entry
Monday, April 4th, 2011 at 9:53 PM
SleepApneaDisorder/ [ Press Release ]/ BELMONT, Calif., April 4, 2011 / — Ventus Medical, Inc. today reported positive results from a 19 center clinical trial using its FDA-cleared Provent® Sleep Apnea Therapy device to treat obstructive sleep apnea. Provent Therapy uses the patient’s own breathing to create expiratory positive airway pressure (EPAP) to keep the airway open during sleep. The full results of this three month study were published in the April 2011 issue of the peer-reviewed medical journal SLEEP, an official publication of the American Academy of Sleep Medicine.
“This randomized, sham-controlled study demonstrates that Provent Therapy significantly improves the apnea hypopnea index (AHI), a scale to measure the number of breathing interruptions or stoppages per hour of sleep, as well as subjective sleepiness, as measured by the Epworth Sleepiness Scale (ESS) in patients with obstructive sleep apnea,” said study author Richard B. Berry, M.D., professor of medicine at the University of Florida College of Medicine, medical director of the University of Florida and Shands Sleep Disorders Center, and former president of the American Sleep Medicine Foundation. “Importantly, self-reported patient adherence on Provent Therapy was almost 90 percent.” Read the rest of this entry